PEG asparaginase

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, University Hospital Muenster, Tanja Andrea Gruber

Conditions

LeukemiaLymphoblastic LeukemiaLymphoblastic LymphomaLymphoblastic Lymphoma, ChildhoodLymphomaPrecursor-B Acute Lymphoblastic Leukemia

Phase 1

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

RecruitingNCT05848687

Tanja Andrea GruberLymphoblastic Leukemia

Start: 2023-11-03End: 2033-12-31Target: 90Updated: 2026-01-13

Phase 2

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

TerminatedNCT02419469

M.D. Anderson Cancer CenterLeukemia, Lymphoblastic Lymphoma, Lymphoma +1

Start: 2015-11-13End: 2017-06-22Updated: 2018-06-11

Phase 3

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

RecruitingNCT04043494

University Hospital MuensterLymphoblastic Lymphoma, Childhood

Start: 2019-08-23End: 2027-11-22Target: 683Updated: 2025-03-21

Related Papers

T‐cell lymphoblastic lymphoma in constitutional mismatch repair deficiency (CMMRD): Exploring treatment opportunities

HemaSphere2024-05-011 citations

Outcome of Infants Treated on Total Therapy for Infants with Acute Lymphoblastic Leukemia I: Results from a Non-Randomized Multi-Center Study

Blood2023-11-026 citations

Design of a targeted next‐generation DNA sequencing panel for pediatric T‐cell lymphoblastic lymphoma to unravel biology and optimize treatment

Genes Chromosomes and Cancer2022-03-122 citations

Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance

Blood2020-11-0553 citations